Search alternatives:
significant estimated » significant estimates (Expand Search), significantly mitigated (Expand Search), significantly overestimated (Expand Search)
aspect decrease » asphalt decreased (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 21 - 40 results of 8,658 for search '(( significant estimated decrease ) OR ( significant ((aspect decrease) OR (larger decrease)) ))', query time: 0.54s Refine Results
  1. 21
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 22
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 23
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 24
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 25
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 26
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 27
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 28
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 29
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 30
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 31
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 32
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 33
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 34
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 35
    Schematics of the orientation delay-estimation experiment and results.

    Schematics of the orientation delay-estimation experiment and results. by Yi-Jie Zhao (11663148)

    Published 2021
    Save to List
    Saved in:
  16. 36
    Larger example of stimuli with cue relevant for Task 3.

    Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

    Published 2024
    Save to List
    Saved in:
  17. 37
    Interareal CFS and PAC decrease as a function of distance.

    Interareal CFS and PAC decrease as a function of distance. by Felix Siebenhühner (383306)

    Published 2020
    Save to List
    Saved in:
  18. 38
    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15.

    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

    Published 2019
    Save to List
    Saved in:
  19. 39
    Parameters used in the simulations.

    Parameters used in the simulations. by Yongfeng Zhu (7361045)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 40
    The CDF of normal and tangential contact forces in numerical specimens after compression considering different particle morphologies: (a) normal contact force; (b) tangential contact force; and different particle sizes: (c) normal contact force; (d) tangential contact force.

    The CDF of normal and tangential contact forces in numerical specimens after compression considering different particle morphologies: (a) normal contact force; (b) tangential conta... by Yongfeng Zhu (7361045)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: